Mitoxantrone
Mitoxantrone is an antineoplastic agent belonging to the anthracenedione class. It acts as a DNA intercalating agent and a topoisomerase II inhibitor, disrupting DNA synthesis and repair. It is also used as an immunomodulator in treating severe active forms of multiple sclerosis.
Dosage by Body Weight
Strictly administered intravenously by a qualified healthcare professional. Dosage is calculated based on Body Surface Area (BSA, mg/m2) rather than body weight alone, depending on the specific condition being treated (MS, leukemia, or prostate cancer). High-alert medication requiring close monitoring of cardiac function and blood counts.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy not established. Chemo dosing is strictly calculated by an oncologist using Body Surface Area (BSA).
- Body Weight
- 5-7 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by oncologist
- Tracking Notes
- Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings.
- Body Weight
- 8-10 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by oncologist
- Tracking Notes
- Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings.
- Body Weight
- 11-15 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by oncologist
- Tracking Notes
- Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings.
- Body Weight
- 16-20 kg
- Dose
- Requires specialist calculation
- Frequency
- As directed by oncologist
- Tracking Notes
- Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy not established. Chemo dosing is strictly calculated by an oncologist using Body Surface Area (BSA). |
| 5-7 kg | Requires specialist calculation | As directed by oncologist | Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings. |
| 8-10 kg | Requires specialist calculation | As directed by oncologist | Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings. |
| 11-15 kg | Requires specialist calculation | As directed by oncologist | Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings. |
| 16-20 kg | Requires specialist calculation | As directed by oncologist | Calculated based on Body Surface Area (BSA). Only administered in specialized clinical settings. |
Formulation
Purpose
Used in the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. Also used to treat hormone-refractory prostate cancer and acute nonlymphocytic leukemia.
Generic Name
MitoxantroneBranded Drug Names
Mitoxantrone is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.